Navigation Links
Aderans Research Acquires Intercytex Assets
Date:3/25/2010

(Atlanta, GA, March 24, 2010) Aderans Research Institute Inc. (ARI) announced it purchased key technology assets from Regenerative Medicine Assets Limited (formerly Intercytex Group plc), a leading UK hair regeneration company.

Atlanta, GA (PRWeb UK) March 25, 2010 -- Aderans Research Institute Inc. (ARI) announced it purchased key technology assets from Regenerative Medicine Assets Limited (formerly Intercytex Group plc), a leading UK hair regeneration company. The acquisition represents a significant consolidation within the hair regeneration industry, as ARI is absorbing the scientific assets of a company that was its leading competitor.

“This acquisition is a major step forward for ARI,” said Vern Liebmann, Vice President, Operations. “Through this deal, we’ve been able to consolidate the majority of key patents and know-how in the hair regeneration field, an achievement that can accelerate our ability to deliver a commercially viable product to market. This acquisition was only possible thanks to the considerable financial support of Aderans Holdings Company, Ltd., of Japan.”

The purchase includes assets related to the ICX-TRC product that Regenerative Medicine Assets Limited had been developing. ICX-TRC is an autologous hair regeneration therapy for the treatment of male pattern baldness and female diffuse alopecia.

The deal comes as ARI is expanding its Phase 2 clinical study of cell-based hair regeneration, in which it recently treated the trial’s 100th subject. “We’ve acquired important proprietary knowledge that includes Intercytex’s clinical efforts to date,” noted Ken Washenik, MD PhD, Executive Vice President. “This information should substantially augment our ongoing efforts to produce a cell-based treatment for hair loss.”

“Cellular regeneration represents the leading edge of research into hair loss,” said Kurt Stenn, MD, Vice President and Chief Scientific Officer. “Combining the knowledge stores of two of the leading companies in this field is a major step forward in our efforts to pioneer a process of cellular hair regeneration that can deliver enhanced hair growth to millions of people around the world.”

About Aderans Research

Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. With offices in Atlanta and Philadelphia, Aderans Research Institute is a subsidiary of Aderans Holdings Company, Ltd., the world’s largest wig manufacturer, and an affiliate of Bosley, a global leader in medical hair restoration.

More information on ARI’s study outcomes will be released as studies unfold. To see ARI’s latest clinical updates, please visit http://aderansresearch.com/ari_clinicalupdates.html

Additional information on ARI can be found at www.aderansresearch.com.

Learn more about Aderans Holdings Company, Ltd. at http://www.aderans.co.jp/e/company/

###

Read the full story at http://www.prweb.com/releases/2010/03/prweb3774184.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Aderans Research Treats One-Hundredth Subject in Clinical Study
2. Researchers Identify 2 Genes Linked to Fatty Liver Disease
3. NIA researchers find gene to explain mouse embryonic stem cell immortality
4. Researchers discover fundamental step in immune-system development
5. Sino Veda Herbal Product Maker Goes Natural in Edmonton Research Park
6. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
7. BHR Pharma Statement on Brain Injury Awareness Month - Better Awareness, Treatment, Research Needed Now
8. Childrens Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami
9. Innovative Service Revolutionizes How Businesses Research Product Sales Potential
10. MAYO Communications Retained by MAMMOJAM 2010 Dr. Susan Love Research Foundation Event
11. Society for New Communications Research Receives Grant to Help Raise Awareness and Reduce Racial and Ethnic Health Disparities
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Aderans Research Acquires Intercytex Assets 
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: